Interview: Mark Yang, Country Manager, Hospira Taiwan
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Address: 18F, 333 DunHua S. Rd., Sec. 2, DaAn District, Taipei 10669, 10669 台北市敦化南路二段333號18樓,Taiwan
Tel: +886 3 3865117
Hospira is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™ through the right people and the right products. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions.
The name ‘Hospira’ is derived from the words hospital, spirit, inspire and the Latin word spero, which means hope. It reflects the company’s primary market focus and expresses the hope and optimism that are critical in the healthcare industry.
Hospira focuses mainly on medical devices in the Taiwanese market, but is currently looking to expand its portfolio and increase its offering of generic drugs.
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for…
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
See our Cookie Privacy Policy Here
